









Markets
/
Stocks
/
nasdaq-enov
/

Enovis Corp

ENOV

31.240USD

+0.550+1.79%

Close 10/31, 16:00（ET）Quotes delayed by 15 min

1.79BMarket Cap

LossP/E TTM



Enovis Corp

31.240

+0.550+1.79%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Enovis Corp

Currency: USD Updated: 2025-10-31

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Enovis Corp's Score

Industry at a Glance

Industry Ranking

37 / 210

Overall Ranking

122 / 4618

Industry

Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

51.750

Target Price

+68.62%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Enovis Corp Highlights

StrengthsRisks

Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment develops, manufactures, and distributes rigid bracing products, orthopedic soft goods, vascular systems and compression garments, and hot and cold therapy products and offers recovery sciences products in the clinical rehabilitation and sports medicine markets, such as bone growth stimulators and electrical stimulators used for pain management. The Reconstructive segment develops, manufactures, and markets a variety of knee, hip, shoulder, elbow, foot, ankle, and finger implant products and surgical productivity tools. It also provides Novastep, a minimally invasive surgery (MIS) foot and ankle solutions.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 34.84% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 2.11B.

Overvalued

The company’s latest PE is -2.10, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 69.40M shares, decreasing 5.26% quarter-over-quarter.

Held by Chuck Royce

Star Investor Chuck Royce holds 2.42M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.36.

Financial Health

Currency: USD Updated: 2025-10-31

The company's current financial score is 6.84, which is lower than the Healthcare Equipment & Supplies industry's average of 7.46. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 564.54M, representing a year-over-year increase of 7.50%, while its net profit experienced a year-over-year increase of 97.12%.

Score

Industry at a Glance

Previous score

6.84

Change



Financials

6.83

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

6.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

7.44

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.26

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.22

Key Metrics

Free cash flow

No Data

Enovis Corp's Company Valuation

Currency: USD Updated: 2025-10-31

The company’s current valuation score is 8.24, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -2.10, which is -17.61% below the recent high of -1.73 and -12693.12% above the recent low of -268.13.

Score

Industry at a Glance

Previous score

8.24

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 37/210

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-31

The company’s current earnings forecast score is 8.40, which is higher than the Healthcare Equipment & Supplies industry's average of 7.74. The average price target for Enovis Corp is 52.50, with a high of 60.00 and a low of 41.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

No Data

Analyst Rating

Based on 10 analysts

Buy

Current Rating

51.750

Target Price

+65.65%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

110

Total

Median

Average

Company name

Ratings

Analysts

Enovis Corp

ENOV

Medtronic PLC

MDT

Stryker Corp

SYK

Abbott Laboratories

ABT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-31

The company’s current price momentum score is 6.89, which is higher than the Healthcare Equipment & Supplies industry's average of 6.65. Sideways: Currently, the stock price is trading between the resistance level at 34.01 and the support level at 28.73, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.72

Change

0.17

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.171

Neutral

RSI(14)

47.665

Neutral

STOCH(KDJ)(9,3,3)

30.101

Sell

ATR(14)

1.171

Low Volatility

CCI(14)

-98.639

Neutral

Williams %R

57.577

Sell

TRIX(12,20)

0.172

Sell

StochRSI(14)

24.569

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

31.928

Sell

MA10

32.245

Sell

MA20

31.574

Sell

MA50

31.415

Sell

MA100

30.759

Buy

MA200

34.291

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-31

The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.43. The latest institutional shareholding proportion is 121.42%, representing a quarter-over-quarter increase of 11.28%. The largest institutional shareholder is The Vanguard, holding a total of 6.37M shares, representing 11.14% of shares outstanding, with 13.88% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

8.02M

+22.95%

The Vanguard Group, Inc.

Star Investors

6.37M

+4.74%

American Century Investment Management, Inc.

4.74M

+34.39%

Dimensional Fund Advisors, L.P.

2.92M

-0.24%

Davenport Asset Management

2.76M

-3.06%

Dorsey Asset Management LLC

2.55M

State Street Investment Management (US)

2.49M

+31.27%

Royce Investment Partners

Star Investors

2.42M

-2.89%

Hood River Capital Management LLC

1.74M

+20.31%

River Road Asset Management, LLC

1.44M

+3.45%

Risk Assessment

Currency: USD Updated: 2025-10-31

The company’s current risk assessment score is 5.89, which is higher than the Healthcare Equipment & Supplies industry's average of 4.56. The company's beta value is 1.45. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.